First Patient Dosed with Leriglitazone in Ongoing FRAMES Trial in FA – Friedreich’s Ataxia News

A patient with Friedreich’s ataxia has been dosed with Minoryx Therapeutics’ investigational therapy leriglitazone in the ongoing Phase 2 FRAMES trial, the company announced. This first patient was enrolled at the Hospital La Paz in Madrid, and was administered the new therapy at the end of April by Dr. Francisco Javier Rodríguez de Rivera and his team.

Read more at:

Font Resize